Cidara Therapeutics, Inc. is running Phase III trials for two separate indications of its novel echinocandin antifungal agent, but while rezafungin might reach market first as a treatment for candidemia and invasive candidiasis, the firm says a second indication for infection prophylaxis in hematologic cancer settings may offer improved outcomes for patients and cost savings for the health care system.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
